Qijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021.

Top

Categories:Qijian News
Author:
Origin:
Time of issue:2021-12-01 13:43
Views:

(Summary description)Qijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021.





Qijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021.

Top

Categories:Qijian News
Author:
Origin:
Time of issue:2021-12-01 13:43
Views:

Information

ijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021.

Previous: Legal Statement

Next: Qijian was invited to participate in "China Service Trade Fair 2021”

Previous: Legal Statement

Next: Qijian was invited to participate in "China Service Trade Fair 2021”

Welcome leaders of Jilin Provincial Department of Commerce to Qijian Bio-Pharmaceutical for investigation

In March 2024, the leaders of the High-Tech Products I&E Department of Jilin Provincial Department of Commerce visit Qijijan Bio-Pharmaceutical for investigation.

发布时间 : 2024-04-02 点击 : 0

In 2024，Jilin Qijian Bio-Pharmaceutical Co., Ltd will take part in the following worldwide professional exhibitions, welcome to visit us

1. 2024.5.7- 2024.5.9, CPHI North America to be held in Philadelphia USA, Address: Pennsylvania Covention Center Philadelphia, Booth number: 1602 2. 2024.6.4-2024.6.6 FCE Pharma to be held in Sao Paulo Brazil, Address: Sao Paulo Expo, Booth number: CH76

发布时间 : 2024-03-19 点击 : 0

API (Butylphthalein) R&D Site, Production Site Verification and GMP Compliance Inspection of Jilin Qijian Bio-Pharmaceutical Co.,Ltd successfully passed.

发布时间 : 2023-09-26 点击 : 0

CPHI Worldwide will be held in Barcelona, Spain on October 24-26, 2023.Jilin Qijian Bio-Pharmaceutical Co.,Ltd will attend the exhibition, Booth No: 80Q19, welcome to visit us.

发布时间 : 2023-09-26 点击 : 0

Great News! Qijian has obtained the human growth hormone (HGH) API export license signed and approved by the Food and Drug Administration。

In early 2022, Jilin Provincial Food and Drug Administration announced our "Drug export license for anabolic agents and peptide hormones" on website, it means that Qijian has become an approved enterprise for export human growth hormone (HGH) API in Jilin Province. Moreover in April 2021 Qijian obtained the "Drug Production License" for product HGH which updated and issued by CFDA, and the quality of HGH products meet the US FDA and EU GMP standards. In the new year, we will continue to improve our management level and provide customers with better products. 注：出口准许证获批公示连接地址吉林省药品监督管理局核（换）发《药品生产许可证》公告（2022年第1期）公示连接地址药品生产许可查询地址

发布时间 : 2022-01-24 点击 : 0

Jilin Qijian Bio-Pharmaceutical Co., Ltd. participated in the 2023CPHI Southeast Asia Exhibition

CPHI South East Asia 2023 has been held at Queen Sirikit National Convention Center, Bangkok, Thailand from July 12-14, 2023.

发布时间 : 2023-07-17 点击 : 0

Home

Tel

Feedback

Qijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021. Top

Qijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021. Top

Welcome leaders of Jilin Provincial Department of Commerce to Qijian Bio-Pharmaceutical for investigation

In 2024，Jilin Qijian Bio-Pharmaceutical Co., Ltd will take part in the following worldwide professional exhibitions, welcome to visit us

API (Butylphthalein) R&D Site, Production Site Verification and GMP Compliance Inspection of Jilin Qijian Bio-Pharmaceutical Co.,Ltd successfully passed.

CPHI Worldwide will be held in Barcelona, Spain on October 24-26, 2023.Jilin Qijian Bio-Pharmaceutical Co.,Ltd will attend the exhibition, Booth No: 80Q19, welcome to visit us.

Great News! Qijian has obtained the human growth hormone (HGH) API export license signed and approved by the Food and Drug Administration。

Jilin Qijian Bio-Pharmaceutical Co., Ltd. participated in the 2023CPHI Southeast Asia Exhibition

Qijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021.

Top

Qijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021.

Top